Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus immunotherapy maintenance after chemo-immunotherapy and thoracic radiotherapy in ES-SCLC (phase III)
ChiCTR2500106276Phase 3Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of anlotinib in small cell lung cancer (SCLC) (2 arms), sponsored by Yantai Yuhuangding Hospital. Primary endpoints: median progression-free survival and 3-year survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500106276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106276.